To read the full article sign up for free or sign in.

Staidson testing MAb combo as potential COVID-19 therapy

Aug. 17, 2022

Staidson Biopharmaceuticals Co. Ltd. is testing a combination of two monoclonal antibodies (MAb), STSA-1002 and STSA-1005, in China for the potential treatment of people with severe-to-critical COVID-19.

BioWorld Clinical Coronavirus Monoclonal antibody China

Today's news in brief

BioWorld

BioWorld briefs for March 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 31, 2025

CMV history cited in DMD liver death on Sarepta’s Elevidys

BioWorld

Wall Street was weighing the gravity of the death from acute liver failure of a patient who was treated for Duchenne muscular dystrophy (DMD) with Sarepta...

UK government abolishes NHS England

BioWorld MedTech

In a move that surprised many across the health care sector, the U.K. government decided to scrap NHS England, the body which runs the national health service...

Sofinnova adds €165M to boost European startups

BioWorld

Leading pharma companies have pitched into Sofinnova Partners’ new accelerator fund, which has exceeded the target and closed at €165 million (US$180 million). In...